Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Plasma Cell Leukemia: early-phase trial registry
8 of 13 indexed Plasma Cell Leukemia trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,315 of 28,707 conditions by registered trial count.
13 US clinical trials · 8 currently recruiting · #1,315 of 28,707 conditions by registered trial count
Plasma Cell Leukemia: 13 US clinical trials tracked, 8 recruiting.
Plasma Cell Leukemia is the subject of 13 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Masonic Cancer Center, University of Minnesota, running 3 of these trials.
Enrollment posture brief
Registry condition plasma-cell-leukemia
OPEN 8 | RECR 62% | LATE 0 | EARLY 9 | RANK #1315 | SPON 3
Volume-matched condition peers
Nearest open-share peer: High Risk Myelodysplastic Syndrome (62% recruiting · 13 trials)
Plasma Cell Leukemia lists 8 open slots (62% of 13 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Plasma Cell Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Plasma Cell Leukemia is recruiting above its size-band peers.
8 of 13 indexed trials (61.5%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Plasma Cell Leukemia research.
Masonic Cancer Center, University of Minnesota accounts for 3 of 13 trials (23.1%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Plasma Cell Leukemia trials plan to enrol fewer than 100 people.
Median target enrolment is 56 among the 13 trials that report a genuine target (sentinel values excluded). 8 of those (61.5%) plan for fewer than 100 participants.
-
Plasma Cell Leukemia research is mostly interventional.
11 interventional and 2 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
13 total, page 1 of 1
Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
University of Alabama at Birmingham
NCT05556928
Registry for Adults With Plasma Cell Disorders (PCD's)
UNC Lineberger Comprehensive Cancer Center
NCT03717844
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota
NCT03314974
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT01962636
Impact of Budesonide on Incidence of ≥ Gr2 Diarrhea in Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplant
University of Utah
NCT05405387
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
M.D. Anderson Cancer Center
NCT05092451
Allo HSCT Using RIC and PTCy for Hematological Diseases
Masonic Cancer Center, University of Minnesota
NCT05805605
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
University of Utah
NCT06517017
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
University of Washington
NCT03389347
Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT05823571
Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants
H. Lee Moffitt Cancer Center and Research Institute
NCT00307086
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
City of Hope Medical Center
NCT01163357
Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma
OHSU Knight Cancer Institute
NCT02504359
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Plasma Cell Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Plasma Cell Leukemia trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Plasma Cell Leukemia page
13 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 8 Plasma Cell Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Masonic Cancer Center, University of Minnesota sponsors the most Plasma Cell Leukemia trials on record, review their full trial history before evaluating a specific study. See Masonic Cancer Center, University of Minnesota's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Plasma Cell Leukemia condition card totals 13 registered trials; most-linked intervention Cyclophosphamide; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.